Management of Cushing disease
- PMID: 21301487
- DOI: 10.1038/nrendo.2011.12
Management of Cushing disease
Abstract
Cushing disease is caused by a corticotroph tumor of the pituitary gland. Patients with Cushing disease are usually treated with transsphenoidal surgery, as this approach leads to remission in 70-90% of cases and is associated with low morbidity when performed by experienced pituitary gland surgeons. Nonetheless, among patients in postoperative remission, the risk of recurrence of Cushing disease could reach 20-25% at 10 years after surgery. Patients with persistent or recurrent Cushing disease might, therefore, benefit from a second pituitary operation (which leads to remission in 50-70% of cases), radiation therapy to the pituitary gland or bilateral adrenalectomy. Remission after radiation therapy occurs in ∼85% of patients with Cushing disease after a considerable latency period. Interim medical therapy is generally advisable after patients receive radiation therapy because of the long latency period. Bilateral adrenalectomy might be considered in patients who do not improve following transsphenoidal surgery, particularly patients who are very ill and require rapid control of hypercortisolism, or those wishing to avoid the risk of hypopituitarism associated with radiation therapy. Adrenalectomized patients require lifelong adrenal hormone replacement and are at risk of Nelson syndrome. The development of medical therapies with improved efficacy might influence the management of this challenging condition.
Similar articles
-
Updates in the outcomes of radiation therapy for Cushing's disease.Best Pract Res Clin Endocrinol Metab. 2021 Mar;35(2):101514. doi: 10.1016/j.beem.2021.101514. Epub 2021 Mar 10. Best Pract Res Clin Endocrinol Metab. 2021. PMID: 33814300 Review.
-
Factors predicting the duration of adrenal insufficiency in patients successfully treated for Cushing disease and nonmalignant primary adrenal Cushing syndrome.Endocrine. 2017 Mar;55(3):969-980. doi: 10.1007/s12020-016-1007-5. Epub 2016 Jul 9. Endocrine. 2017. PMID: 27395418
-
Radiotherapy as a tool for the treatment of Cushing's disease.Eur J Endocrinol. 2019 May 1;180(5):D9-D18. doi: 10.1530/EJE-19-0092. Eur J Endocrinol. 2019. PMID: 30970325 Review.
-
Characterizing and predicting the Nelson-Salassa syndrome.J Neurosurg. 2017 Dec;127(6):1277-1287. doi: 10.3171/2016.9.JNS161163. Epub 2017 Jan 13. J Neurosurg. 2017. PMID: 28084914
-
Treatment options for Cushing disease after unsuccessful transsphenoidal surgery.Neurosurg Focus. 2007;23(3):E8. doi: 10.3171/foc.2007.23.3.10. Neurosurg Focus. 2007. PMID: 17961031 Review.
Cited by
-
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.J Clin Invest. 2011 Dec;121(12):4712-21. doi: 10.1172/JCI60417. Epub 2011 Nov 21. J Clin Invest. 2011. PMID: 22105169 Free PMC article.
-
Recent developments in drug therapy for Cushing's disease.Drugs. 2013 Jun;73(9):907-18. doi: 10.1007/s40265-013-0067-6. Drugs. 2013. PMID: 23737437 Review.
-
Course of Cushing`s disease and treatment outcomes in correlation with pituitary MRI in children.Probl Endokrinol (Mosk). 2022 Apr 12;68(3):93-104. doi: 10.14341/probl12854. Probl Endokrinol (Mosk). 2022. PMID: 35841173 Free PMC article. English.
-
Effectiveness of Medical Treatment of Cushing's Disease: A Systematic Review and Meta-Analysis.Front Endocrinol (Lausanne). 2021 Sep 17;12:732240. doi: 10.3389/fendo.2021.732240. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34603209 Free PMC article.
-
Remission in Cushing's disease is predicted by cortisol burden and its withdrawal following pituitary surgery.J Endocrinol Invest. 2021 Sep;44(9):1869-1878. doi: 10.1007/s40618-020-01495-z. Epub 2021 Jan 16. J Endocrinol Invest. 2021. PMID: 33453019
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources